University of Alabama at Birmingham (UAB) Adult CBD Program
Public ClinicalTrials.gov record NCT02700412. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and tolerability of Epidiolex at various doses between 5 mg/kg/day and 50 mg/kg/day as an additional (add-on) drug for treating debilitating, drug-resistant epilepsy.
Study identification
- NCT ID
- NCT02700412
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 80 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2015
- Primary completion
- Aug 7, 2019
- Completion
- Aug 7, 2019
- Last update posted
- May 7, 2020
2015 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Epilepsy trials
Other public records listing Epilepsy. Sorted by last update posted; newest first. Not a recommendation.
- NCT07768618: Electrophysiologic Mechanisms of Ketamine Antidepressant Response Not yet recruiting
- NCT07750496: Outcomes After Planned Discontinuation of AntiSeizure Medication Recruiting
- NCT07735715: HOBSCOTCH-YOUTH and Young Adults Not yet recruiting
- NCT06135285: A Device to Prevent Sudden Unexpected Death in Epilepsy: Detecting Peri-Ictal Body Position Not yet recruiting
- NCT05954182: Cognitive Enhancement Intervention for Creating a Healthy L.I.F.E (Lifestyle Interventions for Epilepsy) Active, not recruiting
- NCT04715646: A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02700412, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2020 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02700412 live on ClinicalTrials.gov.